What compounds target RPS6KA6?

BiohacksAI has identified 39 compounds that interact with RPS6KA6 (ribosomal protein S6 kinase A6). Top compounds include: sb 203580, tofacitinib, alvocidib, vandetanib, ruxolitinib. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is RPS6KA6 (ribosomal protein S6)?

RPS6KA6 is ribosomal protein S6 kinase A6. It is a molecular target for 39 compounds documented in PubMed bioassay data. UniProt ID: Q9UK32. NCBI Gene ID: 27330.

RPS6KA6

MOLECULAR TARGET

ribosomal protein S6 kinase A6

UniProt: Q9UK32 NCBI Gene: 2733039 compounds

RPS6KA6 (ribosomal protein S6 kinase A6) is targeted by 39 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting RPS6KA6

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	sb 203580	4.92	136
2	tofacitinib	4.65	104
3	alvocidib	4.52	91
4	vandetanib	4.30	73
5	ruxolitinib	4.23	68
6	bosutinib	4.08	58
7	bi 2536	4.01	54
8	midostaurin	3.85	46
9	brigatinib	3.81	44
10	silmitasertib	3.78	43
11	sb 202190	3.64	37
12	nintedanib	3.61	36
13	tae 684	3.43	30
14	fedratinib	3.40	29
15	sgi 1776	3.26	25
16	dovitinib	3.09	21
17	at 9283	3.09	21
18	lestaurtinib	3.04	20
19	pf 03758309	3.00	19
20	ruboxistaurin	2.94	18
21	k 252a	2.83	16
22	sotrastaurin	2.77	15
23	pha 665752	2.71	14
24	crenolanib	2.71	14
25	bms 345541	2.71	14
26	kw 2449	2.64	13
27	ast 487	2.56	12
28	gsk 461364	2.40	10
29	azd 7762	2.30	9
30	su 014813	2.20	8
31	enzastaurin	2.08	7
32	tg100 115	2.08	7
33	cerdulatinib	1.95	6
34	whi p131	1.95	6
35	pf 03814735	1.79	5
36	ucn 01	1.79	5
37	Sorafenib	1.39	3
38	Afatinib	0.69	1
39	pictilisib	0.69	1

About RPS6KA6 as a Drug Target

RPS6KA6 (ribosomal protein S6 kinase A6) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 39 compounds with documented RPS6KA6 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

RPS6KA6 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.